Q-Med: Year-End Report 2006.STOCKHOLM, Sweden -- Q-Med (STO:QMED) * The Group's revenues from sales of goods and royalties amounted to SEK SEK In currencies, this is the abbreviation for the Swedish Krona. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. 1,303.7 (976.0) million, an increase of 34 percent. * Operating income amounted to SEK 300.0 (111.7) million. * Net income after tax amounted to SEK 212.4 (77.1) million. * Earnings per share after full dilution were SEK 2.14 (0.78). * Net income after tax for the fourth quarter amounted to SEK 25.7 (30.3) million. * Collaboration agreement concerning the development and commercialization of botulinum toxin products, entered into with Medy-Tox Inc. in February 2007. * Q-Med's product for fecal incontinence, SOLESTA, approved for sales in Europe. * The Board has adopted a new dividends policy, whereby it is proposed that approximately 50 percent of profit after tax is paid out as a regular dividend. * The Board intends to propose to the AGM AGM annual general meeting AGM n abbr (= annual general meeting) → AG f AGM n abbr (= annual general meeting) → JHV f a dividend of SEK 2 per share, of which SEK 1 is regular dividend and SEK 1 extra dividend. Queries should be addressed to: Erika Kjellberg Eriksson, Vice President and CFO See Chief Financial Officer. Tel: + 46 70-974 90 20. Coming reports: Interim report January - March 2007 May 3, 2007 Interim report January - June 2007 July 26, 2007 Interim report January - September 2007 October 23, 2007 Annual General Meeting: May 3, in Uppsala Chairman of the election committee: Robert Wikholm, robert.wikholm@vinge.se Q-Med AB is a rapidly growing and profitable biotechnology/medical device company. The company develops, produces, markets and sells implants for esthetic and medical use. All products are primarily based on the company's patented technology for the production of stabilized non-animal hyaluronic acid, NASHA NASHA Non-Animal, Stabilized Hyaluronic Acid (trademark of Q-Med AB; Uppsala, Sweden) NASHA National Association for Speech and Hearing Action (Rockville, MD) [TM]. The product portfolio today contains: RESTYLANE for the filling out of lips and facial wrinkles and for facial contouring, DUROLANE, for the treatment of osteoarthritis of the hip and knee joints, DEFLUX for the treatment of vesicoureteral reflux, VUR VUR Vesicoureteral reflux, see there , (a malformation malformation /mal·for·ma·tion/ (-for-ma´shun) 1. a type of anomaly. 2. a morphologic defect of an organ or larger region of the body, resulting from an intrinsically abnormal developmental process. of the urinary bladder) in children, ZUIDEX, for the treatment of stress urinary incontinence stress urinary incontinence n. See stress incontinence. in women and SOLESTA, for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has just over 600 co-workers, with approximately 400 at the company's head office and production facility in Uppsala, Sweden. The Q-Med share is listed in the Large Cap segment of the OMX OMX Office Max (stock symbol) Nordic Stock Exchange in Stockholm. NASHA, DUROLANE, SOLESTA, ZUIDEX, IMPLACER, DEFLUX and all product names within the RESTYLANE family are trademarks that belong to Q-Med. This information was brought to you by Waymaker http://www.waymaker.net |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion